Antibody-drug conjugates (ADCs), particularly the HER2-targeting Enhertu (DS-8201), have revolutionized targeted cancer therapy by combining the specificity of monoclonal antibodies with cytotoxic payloads. Despite their clinical success, drug resistance remains a major hurdle limiting long-term therapeutic benefits. To address this challenge, GemPharmatech has developed multiple ADC resistance models.

These include a HER2-positive JIMT-1 breast cancer xenograft (CDX) model with acquired resistance to Enhertu, established through in vivo drug induction. Additionally, utilizing Enhertu drug sensitivity testing, we have screened for a primary Enhertu-resistant HER2-positive lung cancer model from our extensive patient-derived xenograft (PDX) library.

These Enhertu-resistant models serve as translational tools to elucidate resistance mechanisms—particularly those not yet observed in the clinic—and to evaluate novel therapeutic strategies. Key applications include testing combination therapies targeting multiple pathways or supporting the preclinical development of next-generation ADCs with improved therapeutic efficacy.

Key topics include:

• Overview of GemPharmatech’s ADC evaluation platform

• Construction and validation of an Enhertu-induced resistant CDX model

• Investigation of underlying resistance mechanisms

• Characterization of a primary Enhertu-resistant PDX model

Date: Tuesday, April 14, 2026

Time: 8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 5:00 PM CEST

Duration: One Hour